| II-17 Nicolas Frey Bridging from Intravenous to Subcutaneous Formulation of Tocilizumab for Optimal Dose Regimens in Systemic Juvenile Idiopathic Arthritis Wednesday 15:50-17:20 |
| II-17 Nicolas Frey Bridging from Intravenous to Subcutaneous Formulation of Tocilizumab for Optimal Dose Regimens in Systemic Juvenile Idiopathic Arthritis Wednesday 15:50-17:20 |